Skip to main content

Table 2 Significantly up- and down-regulated genes that discriminate resistant (R) from sensitive (S) CLL patients and that are common to males (M) and females (F)

From: Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELBin an aggressive subset of chronic lymphocytic leukemia in males

Gene name* Gene Symbol Chromosome Location Fold change RM vs. SM Fold change RF vs. SF
trafficking protein, kinesin binding 2 TRAK2 2q33 0.054 0.379
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit CACNA1A 19p13.2-p13.1 0.116 0.135
contactin associated protein-like 2 CNTNAP2 7q35-q36 0.003 0.060
C-terminal binding protein 1 CTBP1 4p16 0.290 2.344
discs, large (Drosophila) homolog-associated protein 4 DLGAP4 20q11.23 0.164 0.389
DNA polymerase-transactivated protein 6 DNAPTP6 2q33.1 0.199 0.177
developmentally regulated GTP binding protein 2 DRG2 17p11.2 0.320 0.442
G protein pathway suppressor 2 GPS2 17p13 0.430 0.425
HOM-TES-103 tumor antigen-like HOM-TES-103 12p13.3 0.303 0.446
integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide) ITGAE 17p13 0.450 0.434
phosphoribosylformylglycinamidine synthase (FGAR amidotransferase) PFAS 17p13.1 0.320 0.457
pleckstrin homology domain containing, family B (evectins) member 1 PLEKHB1 11q13.5-q14.1 0.203 0.484
RNA binding motif, single stranded interacting protein 1 RBMS1 2q24.2 0.036 0.352
v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 RELB 19q13.31-q13.32 0.245 3.033
transmembrane protein 33 TMEM33 4p13 0.203 2.013
vesicle-associated membrane protein1, synaptobrevin1 VAMP1 12p 0.287 0.395
vanin 2 VNN2 6q23-q24 0.434 0.424
  1. *Genes listed were identified as being differentially expressed after direct comparisons of gene expression profiles between resistant and sensitive CLL samples for males and females. FC, fold change